BioSpace News Archive

Policy

WHO Issues Guidance Against Convalescent Plasma for COVID-19

The WHO’s latest decision is based on advice from an independent panel of experts who evaluated data from 16 randomized controlled studies.

December 7, 2021
·
2 min read
·
Vanessa Doctor, RN
Genetown

Odyssey to Aim $218 Million at Novel Targets

Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.

December 7, 2021
·
3 min read
·
Mark Terry
Drug Development

Merck Pauses Two More HIV Trials in Light of Recent Findings

The news comes just three weeks after Merck paused its Phase II IMAGINE-DR trial, which was studying a combination of islatravir with MK-8507.

December 7, 2021
·
2 min read
·
Heather McKenzie
Business

Alvotech Unites with Oaktree in $2.25 Billion Merger to Advance Biosimilars

Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.

December 7, 2021
·
2 min read
·
Vanessa Doctor, RN
Deals

Recursion and Roche Ink Multi-Billion Dollar AI Deal

Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.

December 7, 2021
·
2 min read
·
Alex Keown
Genetown

What Omicron Could Teach Us About Predicting Future COVID-19 Variants

Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.

December 7, 2021
·
7 min read
·
Mark Terry
Drug Development

Alzheimer’s and Dementia: The Latest Developments

Researchers are working to develop new treatments for Alzheimer’s disease and dementia and improve the already existing ones. Find out more here.

December 7, 2021
·
9 min read
·
Mishayl Hanan
Business

vTv Slashes 65% of Workforce to Push Diabetes Program through Phase III

vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company’s future growth.

December 7, 2021
·
2 min read
·
Alex Keown
Business

Former Scripps and Humira Leader Richard Lerner Passes Away

Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.

December 7, 2021
·
3 min read
·
Alex Keown
Drug Development

LAG-3 Pioneer Frédéric Triebel Discusses Its Potential in Immunotherapy

LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.

December 7, 2021
·
5 min read
·
Heather McKenzie